A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A

Abstract

Introduction:Vestibular migraine is a clinical entity characterised by dizziness. Additionally, it has no proven treatment options, and the goal is to control vestibular symptoms by reducing migraine attacks. This study aimed to investigate the effect of onabotulinum toxin type A in reducing vestibular migraine symptoms.Methods:Between 2014 and 2019, the charts of 80 patients with migraine who received onabotulinum toxin type A treatment were collected. Among them, 22 patients who met the criteria of vestibular migraine were included in the study. The treatment outcomes of these patients were investigated. Migraine Disability Assessment scale (MIDAS), Visual Analogue scale (VAS) and Dizziness Handicap index (DHI) were used for evaluation. Pre-treatment and post-treatment values were compared.Results:The mean age of the patients was 41.5 years. When MIDAS, DHI and VAS scores were compared, the post-treatment scores were found to be statistically significantly lower than the pre-treatment scores (p<0.05).Conclusion:Botulinum toxin treatment may be promising in patients with vestibular migraine. The limitation of this study is our relatively small group of patients. Therefore, there is a need for prospective work with a larger group of patients.

Keywords

• vestibular migraine
• onabotulinum toxin type a
• dizziness
• headache